Vitamin D and nifedipine in the treatment of Chinese patients with grades I–II essential hypertension: A randomized placebo-controlled trial
Atherosclerosis, Volume 235, Issue 1, Pages 102–109, July 2014, http://dx.doi.org/10.1016/j.atherosclerosis.2014.04.011
Wei Ren Chen1, Zhi Ying Liu1, Yang Shie chen_weiren at sina.com , Da Wei Yin, Hao Wang, Yuan Sha, Yun Dai Chen
1These authors contributed equally to this work.
Received: December 4, 2013; Received in revised form: March 28, 2014; Accepted: April 7, 2014; Published Online: April 30, 2014, DOI:
Highlights
•We planned to research the effect of vitamin D and nifedipine in the treatment of patients with essential hypertension.
•Vitamin D supplementation can reduce blood pressure in patients with hypertension.
•Vitamin D supplementation can be an adjuvant therapy for patients with grade I to II essential hypertension.
Objectives
Low vitamin D status has been shown to be associated with hypertension. We planned to research the effect of vitamin D and nifedipine in the treatment of patients with essential hypertension.
Methods
Patients with grades I–II essential hypertension were enrolled in this single-center, double-blind, placebo-controlled trial in Beijing. All patients received a conventional antihypertensive drug (nifedipine, 30 mg/d). One hundred and twenty-six patients were randomly assigned to receive vitamin D (n=63, 2000 IU/d) or a placebo (n=63) as an add-on to nifedipine, by the method of permutated block randomization. Ambulatory blood pressure monitoring was performed at baseline (month 0), at month 3 and at month 6.
Results
In vitamin D supplementation group, there was a significant increase in mean 25-hydroxyvitamin D levels from baseline (19.4±11.6 ng/ml) to 6 months (34.1±12.2 ng/ml; p<0.001). At 6 months, the primary end points, a difference in the fall of 24-h mean blood pressure, between the groups was
- −6.2 mmHg (95% CI −11.2; −1.1) for systolic blood pressure (p<0.001) and
- −4.2 mmHg (95% CI −8.8; −0.3) for diastolic blood pressure (p<0.001)
under intention to treat analysis.
In patients with vitamin D <30 ng/ml at baseline (n=113), 24-h mean blood pressure decreased by 7.1/5.7 mmHg (p<0.001). Safety and tolerability were similar among the two groups.
Conclusions
Vitamin D supplementation can reduce blood pressure in patients with hypertension, it can be an adjuvant therapy for patients with grades I–II essential hypertension.
Clinical Trial Registration: This study was registered in the Chinese Clinical Trial Registry, it is available in Website: http://www.chictr.org/cn/; Registration number: ChiCTR-ONC-13003840.
VitaminDWiki - Hypertension category contains
see also
Overview Overview Hypertension and Vitamin D
Overview Cardiovascular and vitamin D
Overview Stroke and vitamin D
Incidence of 22 health problems related to vitamin D have doubled in a decade
Some interesting Hypertension studies
- Hypertension risk decreased 10X by increasing vitamin D levels to more than 40 ng – Nov 2017
- Hypertension risk reduced 4X if adequate level of Vitamin D – July 2024
- COVID-19 deaths 4 to 7 X more likely if Diabetic, Hypertensive, or CVD - meta-analysis March 2020
- Magnesium reduces hypertension - FDA allows claim - Jan 2022
- Drug-resistant hypertension 3.5 X more likely if low vitamin D – March 2020
- High Blood Pressure reduced by Vitamin D supplementation in seniors and obese – meta-analysis May 2019
- Blood pressure in diabetics reduced by 12 weekly doses of 50,000 IU vitamin D – RCT Jan 2014
- Hypertension is associated with low vitamin D in some groups – meta-analysis April 2015
- Off Topic – Hypertension in 42 percent of adults (new definition: 130 mm Hg) – Feb 2018
- Men aged 40-59 59%, age >60 75%: National Health and Nutrition Examination Survey, 2017–2018
HT related to Pregnancy 38+, Intervention 15+, Cardio. 14+, Diabetes 13+, Stroke 10+, Mg 9+ categories
Title change made June 2022 caused the visitor count to reset.
There have actually been
| 3523 visitors, last modified 23 Jun, 2022, |